Research programme: vaccines - Bharat Biotech

Drug Profile

Research programme: vaccines - Bharat Biotech

Alternative Names: BBV 121; Malaria vaccine - Bharat Biotech; Methicillin-resistant Staphylococcus aureus vaccine - Bharat Biotech; Non-typhoidal salmonella vaccine -Bharat Biotech; NTS conjugate vaccine - Bharat Biotech; Papilloma virus vaccine - Bharat Biotech; Pertussis vaccine - Bharat Biotech; PvR II; Tetanus vaccine - Bharat Biotech; Zika inactivated vaccine - Bharat Biotech; Zika recombinant vaccine - Bharat Biotech; Zika virus vaccine - Bharat Biotech; ZikaVac

Latest Information Update: 04 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bharat Biotech
  • Developer Bharat Biotech; Center for Vaccine Development
  • Class Bacterial vaccines; Viral vaccines
  • Mechanism of Action Duffy antigen binding protein modulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Malaria; Methicillin-resistant Staphylococcus aureus infections; Zika virus infection
  • Research Human papillomavirus infections; Pertussis; Salmonella infections; Tetanus

Most Recent Events

  • 31 May 2017 Bharat Biotech plans a phase I trial for Zika virus infection (In volunteers) in India (CTRI2017-05-008539)
  • 03 Feb 2016 Bharat Biotech files for global patent protection for ZikaVac®
  • 03 Feb 2016 Preclinical trials in Zika virus infection in India (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top